Biotech entity
Pfizer is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. The 170-day window averages about 0.1 stories each week.
Last mentioned: Aug 7, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Pfizer is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. The 170-day window averages about 0.1 stories each week. The 6.3 average consequence score is above the beat benchmark of 6.2 in the same window. clinical-trial accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. This profile follows 3 Biotech stories mentioning Valneva across the period from February 19, 2026 to August 7, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 688 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Valneva. Shared-story counts are live from our verified record — not editorial picks.
Potential Launch
Anticipated commercial availability following regulatory approval and CDC recommendation.
Regulatory Filing
Expected submission of Biologics License Application (BLA) to the FDA.
Pfizer-Valneva regulatory submission planned
Pfizer and Valneva announce they intend to file for approval of their Lyme disease vaccine candidate this spring, according to KFF Health News.
Efficacy Results
Trial data shows over 70% efficacy against Lyme disease in endemic regions.
Phase 3 Initiation
Pfizer and Valneva launch the VALOR Phase 3 clinical trial for VLA15.
LYMErix withdrawn from market
Citing low demand, lawsuits alleging side effects, and mounting public mistrust, the manufacturer pulls the vaccine only three years after launch.
FDA approves LYMErix
SmithKline Beecham (now GSK) receives approval for the first Lyme disease vaccine, aimed at preventing the tick-borne illness.
Pfizer and Valneva’s planned regulatory submission for a new Lyme disease vaccine enters a market haunted by the failure of LYMErix and amplified vaccine skepticism, challenging the blockbuster potential of a shot aimed at 476,000 annual U.S. cases.
Source: sun-sentinel.com · reporterherald.com
Pfizer and Valneva have reported positive Phase 3 results for their Lyme disease vaccine candidate, VLA15, demonstrating an efficacy rate exceeding 70%. This development marks a significant milestone in addressing the growing public health threat of tick-borne illnesses, potentially offering the first preventative vaccine for the disease in over two decades.
A landmark study reveals that the excruciating tropical disease Chikungunya is now capable of local transmission across most of Europe. Driven by the northward migration of the Aedes albopictus mosquito, this shift creates an urgent demand for vaccines and diagnostic infrastructure in previously unaffected regions.
Source: theguardian.com · aol.co.uk
Valneva is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
